EGFR and non-small cell lung carcinoma: In NSCLC, ctDNA could be used to track and examine the effect of “druggable” mutations, e.g., of EGFR, and together with CTCs to identify expression of potentially crucial players and of changes in tumor characteristics before, during, and after appropriate treatments.